Actively Recruiting
Application of FAPI and FDG PET Imaging in Patients With Different Types of Cancer
Led by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Updated on 2024-02-28
2000
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cancer associated fibroblasts (CAFs) can promote tumor cell proliferation, migration, invasion, and angiogenesis through immunosuppressive effects and the production of mediators, thereby promoting tumor growth and progression. The characteristic of CAFs is high expression of fibroblast activation protein (FAP). In approximately 90% of epithelial derived tumors, FAP is highly overexpressed on the membrane of CAFs. Contrary to CAFs, FAP expression is lower or absent in normal tissues. Therefore, FAP inhibitors (FAPI) targeting FAP can overcome the limitations of 18F-2-fluoro.2-deoxy-D-glucose fluorodeoxyglucose(18F-FDG) PET imaging. But like 18F-FDG, wound healing, fibrosis, and inflammation can also uptake FAPI.. Therefore, a comparison of the performance of 18F-FDG and 18F-FAPI PET imaging in diagnosing primary and metastatic lesions of various types of cancer is conducted to evaluate the potential value of these new radiopharmaceuticals as effective alternatives to 18F-FDG, highlighting their advantages and limitations.
CONDITIONS
Official Title
Application of FAPI and FDG PET Imaging in Patients With Different Types of Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients (≥ 18 years old)
- Suspected or newly diagnosed malignant tumor patients
- Patients who underwent 18F-FDG and 18F-FAPI PET scans within one week
- Patients able to provide informed consent forms according to ethics guidelines
You will not qualify if you...
- Pregnant women
- Patients with poor image quality due to body movement or other factors
- Patients with mental illness or other conditions making examination unsuitable or causing poor compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Nuclear Medicine, Daping Hospital of Army Medical University
Chongqing, Chongqing Municipality, China, 400010
Actively Recruiting
Research Team
X
Xiao Chen, Ph.D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here